| Editor’s Note: Fierce Biotech will not publish on Thursday or Friday in observance of the Thanksgiving holiday. We'll be back in your inbox on Monday. Have a great weekend! |
|
January 9-10, 2024 | San Francisco, CA
January 16-18, 2024 | Virtual Don't miss this chance to position your company as an industry leader. Join over 500 senior pharma and biotech executives at this can't miss event! - Thought Leadership
- Branding - Networking
- Exhibit & Meeting Space Register today and Save $450! 
|
|
Today’s Big NewsNov 22, 2023 |
| By Nick Paul Taylor Evelo Biosciences is dissolving. One month after starting a search for strategic alternatives, the Flagship Ventures-backed microbiome biotech has found its only option is to close its doors and hand any cash to creditors. |
|
|
|
By Gabrielle Masson Boehringer Ingelheim is acquiring bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to $508 million. |
By Nick Paul Taylor InDex Pharmaceuticals may be struggling to think of reasons to be thankful. The Swedish biotech has rocked investors with news it is stopping a phase 3 ulcerative colitis trial early in response to lackluster efficacy, sending its share price down 60%. |
Sponsored by Adaptive Biotechnologies Dr. Sharon Benzeno, Chief Commercial Officer of Immune Medicine at Adaptive Biotechnologies, shines a spotlight on the key immune-driven medicine advancements that show immense promise in transforming diagnoses, treatments, and patient outcomes. |
By James Waldron After mulling a potential buyout for a month, Freeline Therapeutics has decided that its future lies in the arms of its majority shareholder. |
Sponsored by Cerba Research There were 250 decentralised clinical trials (DCTs) worldwide in 2012. By 2021, there were 1,291. Dan Tanner, chief commercial officer at Cerba Research, explains how the firm is helping to create a new paradigm in clinical trials. |
By James Waldron Despite Entrada Therapeutics' efforts to persuade the FDA with additional information, the regulatory agency has rejected the company's attempts to lift the nearly yearlong clinical hold on its leading Duchenne muscular dystrophy candidate. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Fraiser Kansteiner In a lawsuit filed in Delaware federal court Monday, AbbVie accused Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals and Sun Pharmaceutical of trying to sidestep dozens of patents protecting Rinvoq through the next decade. |
By Andrea Park As competitor Philips continues to grapple with the effects of its long-standing recall of CPAP machines and other respiratory devices, ResMed is now issuing a safety warning of its own. |
By Fraiser Kansteiner After suffering setbacks in the clinic and in court this week, Bayer’s ability to overhaul its corporate structure is becoming more constricted, one group of analysts contends. |
By Paige Minemyer A City of Hope analysis found that Medicare Advantage members faced a delay of two weeks or more between diagnosis and their first course of therapy. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of "Podnosis," you'll hear from two journalists from the Fierce Healthcare team: Paige Minemyer, senior editor of Fierce Health Payer, and Dave Muoio, a staff writer for Fierce Healthcare. Together, they guide you through their key insights from the inaugural Fierce Health Payer Summit in Austin and dive into the latest earnings updates from the largest health plans and health systems. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape. 
|
|
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| Edison Ballroom, New York City |
|
|
| |
|
